By Dr. Humberto Fernandez Miro, MD | Family Medicine · Clinical Research | April 2026 | WeightLossPills.com
I have been practicing family medicine for over fifteen years. In that time, I have watched the conversation around obesity change more than almost any other topic in primary care. And yet, in a lot of exam rooms, the conversation still goes something like this: the patient comes in, the weight is noted on the chart, and someone says something about diet and exercise.
That conversation is not wrong. But it is incomplete. And when it is the only conversation happening, it does more harm than it does good.
I want to talk about what obesity actually looks like in a real practice — not in a clinical trial, not in a textbook — and why I think we are at a turning point that every primary care physician needs to take seriously.
The Patient Who Changed How I Think About This
A few years ago, I had a patient — mid-forties, worked in logistics, two kids — who had been trying to lose weight for most of his adult life. He had done the programs. He had done the calorie counting. He had lost weight and regained it so many times that he had stopped believing it was something he could actually control. He came in for a blood pressure check. He did not come in to talk about his weight.
I brought it up anyway, which I used to do more reflexively than thoughtfully. I asked him what he had tried. He listed things. I asked if he had considered medication. He looked at me like I had suggested something slightly shameful.
That look stayed with me. Because it told me something I already knew but had not fully reckoned with: we have spent decades making patients feel that needing pharmaceutical help for obesity is a character failure. And we have done this while simultaneously treating high cholesterol, high blood pressure, and type 2 diabetes with medication without anyone flinching.
Obesity is a chronic disease. We have known this for a long time. We do not always act like it.
What the Research Has Been Telling Us
The biology of weight regulation is not simple. Most people, including most physicians, underestimate how aggressively the body defends its set point. When someone loses weight through restriction alone, the body responds. Hunger hormones increase. Metabolism slows. The system fights back, and it fights back hard.
This is not a failure of willpower. This is physiology. And for a long time, we did not have tools that could meaningfully work with that physiology rather than against it.
That has changed.
The GLP-1 receptor agonist class — drugs like semaglutide and tirzepatide — work on the mechanisms that regulate hunger and satiety at a level that diet alone cannot reach. The clinical trial data have been striking enough that it prompted serious reconsideration of how obesity should be classified, treated, and discussed at every level of medicine.
For patients who have failed every behavioral intervention, having a medication that addresses the underlying hormonal environment is not cheating. It is appropriate treatment.
What I Actually See in the Exam Room
When I talk to patients now about the options available to them — including newer weight loss pills and injectable medications — the conversation is different than it was five years ago. Patients come in having already read about semaglutide. They have heard about it from someone they know. They have questions about whether it is right for them, whether their insurance will cover it, whether the side effects are manageable.
Some of them have already tried it. A surprising number have tried compounded versions from telehealth platforms, sometimes without telling their primary care physician, which creates a whole separate set of clinical concerns I have written about elsewhere.
But the shift in how patients are engaging with this topic is real. The stigma has not disappeared, but it has cracked. People who spent years believing that medication was not a legitimate option for them are now asking questions. That is progress.
The Part That Does Not Get Discussed Enough
Here is something I think about a lot: the patients who benefit most from these medications are often the ones who have the hardest time accessing them.
GLP-1 medications are expensive. The coverage landscape is uneven and often unpredictable. Patients who cannot afford brand-name medication sometimes turn to compounded alternatives that may or may not be formulated correctly. Patients in underserved areas may not have access to physicians who are comfortable prescribing these drugs or monitoring their use.
The science is ahead of the access. That is a problem that does not get resolved in the exam room, but it is a problem that every clinician who treats obesity needs to understand.
I also think about the patients who have been failed by the framing of obesity as a behavioral problem for so long that they have given up. They are not showing up asking about medications because they have stopped believing that anything will work. Reaching them requires a different kind of conversation — one that begins with acknowledging what they have been through, not with another list of recommendations.
Where I Think Primary Care Needs to Go
We need to get more comfortable with complexity. Obesity treatment is not one thing. It is behavioral counseling, nutritional support, pharmacological intervention, and in some cases surgery. The best outcomes happen when these things work together, not when one is treated as the right answer and the others are dismissed.
We need to get better at having honest conversations about medication — what it can do, what it cannot do, and what stopping it means. Because the data on weight regain after discontinuation is not subtle. These are not medications you take for six months and stop. That is a conversation that needs to happen before the prescription is written.
And we need to stop treating the visit weight as a proxy for everything. I have patients who are metabolically healthy at weights that would trigger concern on a chart. I have patients who are metabolically compromised at weights that look fine on paper. The number on the scale is one data point. It is not the whole story.
What My Patients Have Taught Me
The patient I mentioned earlier — the one who came in for a blood pressure check — eventually started a GLP-1 medication. Not because I pushed him. Because I explained, without judgment, what the medication did and why it might be different from what he had tried before. He came back three months later. His blood pressure was better. His energy was better. He said, for the first time in years, he did not feel like he was fighting himself every time he sat down to eat.
That is not a miracle. That is medicine working.
The conversation around obesity in primary care is getting better. The tools are getting better. The science is getting better. But the pace of change in the exam room tends to lag behind the pace of change in the literature, and the patients who need us to close that gap are the ones who have already been waiting the longest.
We owe them a better conversation.
About the Author
Dr. Humberto Fernandez Miro, MD is a family medicine physician with a focus on clinical research and chronic disease management. He is a contributing medical reviewer at WeightLossPills.com.
